Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
October 18, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and...
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
September 06, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be...
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
August 09, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5...
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
May 10, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2...
Prelude Therapeutics Reports Full Year 2021 Financial Results
March 16, 2022 07:30 ET
|
Prelude Therapeutics, Inc.
Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives...
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
March 11, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...
Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting
March 09, 2022 08:05 ET
|
Prelude Therapeutics, Inc.
Announces strategic prioritization within lead programs targeting PRMT5 and MCL1 Describes new pipeline candidate, PRT3645, a highly brain penetrant CDK4/6 inhibitor;IND submission planned mid-2022 ...
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
March 09, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been...
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...